In view of the fact that the HGF/MET pathway is relevant in tumor progression and tumorigenesis in diverse types of cancer [6–12, 22], it seems obvious that therapeutic approaches are expected to target either the ligand (HGF) or the receptor (MET). Here, HGF is linked to neoplasm.